Clinical trials: Infectious Panuveitis
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity.
- Trial name
- NCT05384249
- Testing
- Izokibep
- Where
- 69 sites in United States, Austria and 5 more
- Volunteers
- 96 people
- Sponsor
- ACELYRIN Inc.
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Anterior Uveitis
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- EGP-437-006 (NCT02517619)
- Testing
- Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Non-infectious Intermediate, Posterior and Panuveitis
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
- Trial name
- NCT03339102
- Where
- 17 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- AbbVie
Uveitis, Posterior
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.
- Trial name
- NCT05322070
- Testing
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Alimera Sciences
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Uveitis, Uveitis, Posterior
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of…
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- NCT02952001
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 16 sites in United States, India
- Volunteers
- 33 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis Posterior Non-Infectious, Uveitis, Intermediate
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.
- Conditions
- Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis
- Trial name
- OPTYK-1 (NCT05953688)
- Testing
- ESK-001
- Where
- 17 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alumis Inc
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Uveitis
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.
- Trial name
- VISUAL III (NCT01148225)
- Testing
- adalimumab
- Volunteers
- 424 people
- Sponsor
- AbbVie
Uveitis, Posterior, Uveitis, Intermediate
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Uveitis
- Trial name
- CLARITY (NCT06431373)
- Testing
- Brepocitinib PO QD
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 371 people
- Sponsor
- Priovant Therapeutics, Inc.
Uveitis
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
This study will provide patients who have completed the AIN457 Phase II and Phase III clinical trials in non-infectious uveitis continued access to treatment with AIN457 while collecting safety data and information on long term…
- Trial name
- SUPPORT (NCT01327664)
- Testing
- AIN457
- Sponsor
- Novartis Pharmaceuticals
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.
- Trial name
- EYEGUARD™-A (NCT01684345)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 116 sites in United States, Argentina and 20 more
- Volunteers
- 200 people
- Sponsor
- XOMA (US) LLC
Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
- Trial name
- NCT00333996
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Allergan
Noninfectious Intermediate, Posterior, or Panuveitis
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time.
- Trial name
- NCT07861074
- Testing
- Tulisokibart, Background prednisone therapy
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC
Uveitis, Anterior
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment…
- Trial name
- NCT00694135
- Testing
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- Where
- 19 sites in United States, India
- Volunteers
- 40 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- ENDURE (NCT01032915)
- Testing
- AIN457
- Where
- 94 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals